This product includes the webinar and SAM credit
Ahmet Zehir, PhD
Jonathan Nowak, MD, PhD
Description: As tumor mutational burden (TMB) is gaining traction as a predictive biomarker for immunotherapy, the challenge of reporting TMB back to the treating oncologists and patients in an informative way still exists. In this webinar, we will discuss strategies of implementing TMB in the clinical laboratory, how different TMB values reported from various assays compare to each other, and how to communicate the results in a clear way.
Duration: 1 hr
Level of Instruction: Basic
Last day to purchase course and claim credit: December 31, 2020
Maximum SAM credit available: 1.0
This webinar is part 3 of a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.
This program has been supported through an educational grant from Bristol-Myers Squibb.
How to claim credit: To earn SAM credit, all learners must watch the webinar, achieve a minimum score of 80% on the online quiz, and complete an online survey. To access the quiz, click "Submit credit" on the course homepage or click on "My Credit" on the menu to the left and then "submit credit" for the appropriate course.
This course is approved by the American Board of Pathology for 1.0 SAM credits.Physicians should only claim credit commensurate with the extent of their participation in the activity. Participants must successfully complete the online modular exams (answering at least 80% of the questions in a topic module correctly).
SAM questions edited by: Honey Reddi, PhD
* You may not submit SAMs and CME/CMLE credit for the same content.
You may also be interested in:
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.